



THE WHITE HOUSE  
WASHINGTON

# COVID-19 Press Briefing

August 24, 2021



# Daily Change in COVID-19 Cases, US

January 22, 2020 – August 20, 2021

TOTAL Cases Reported Since 1/22/20

**37,583,545**

NEW Cases Reported to CDC on 8/20/21

**157,450**

Change in 7-Day Case Average


**+11.7%**

Current 7-Day Case Average (8/14/21 - 8/20/21)

**137,189**

Prior 7-Day Case Average (8/7/21 - 8/13/21)

**122,770**



# New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – August 21, 2021

Patients Currently Hospitalized with COVID on 8/21/21

**58,393**

New Admissions on 8/21/21

**8,713**

Peak in New Admissions (1/5/21)

**17,963**

Change in 7-Day Average of New Admissions


**+1.6%**

Current 7-Day Average of New Admissions (8/15/21 - 8/21/21)

**11,337**

Prior 7-Day Average of New Admissions (8/8/21 - 8/14/21)

**11,162**



# Daily Change in COVID-19 Deaths, US

January 22, 2020 – August 20, 2021

TOTAL Deaths Reported Since 1/22/2020

625,375

NEW Deaths Reported to CDC on 8/20/21

1,120

Change in 7-Day Death Average

+23.1%

Current 7-Day Death Average (8/14/21 - 8/20/21)


739

Prior 7-Day Death Average (8/7/21 - 8/13/21)

600


Forecasted Total Deaths by 9/11/21

638,000 to 664,000



# COVID-19-associated Hospitalizations among Unvaccinated and Fully Vaccinated

Age-adjusted population-based rates<sup>a</sup> of COVID-19-associated hospitalizations among unvaccinated and fully vaccinated adults aged ≥18 years admitted January 24–July 24, 2021,<sup>b</sup> cumulative — COVID-NET, 13 States<sup>c</sup>



<sup>a</sup>Number of patients with laboratory-confirmed COVID-19-associated hospitalizations per 100,000 population.

<sup>b</sup>COVID-NET hospitalization data are preliminary and subject to change as more data become available. In particular, rates for recent hospital admissions are subject to lag.

<sup>c</sup>California, Colorado, Connecticut, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.



**Monoclonal Antibodies for the  
Treatment and Prevention  
of  
SARS-CoV-2 Infection and  
COVID-19 Disease**




# Monoclonal Antibody




An antibody produced by a single clone of cells or cell line and consisting of *identical* antibody molecules







**SARS-CoV-2 Virion**



**Spike Protein**



**Polyclonal Antibody**




**Monoclonal Antibody**

### **3 Anti-SARS-CoV-2 Monoclonal Antibody Products Currently Have Emergency Use Authorizations (EUAs) From the FDA**

---

- **EUAs for adults and children 12 years and older who weigh at least 88 pounds (40 kg)**
  - Bamlanivimab plus etesevimab – Lilly
  - Casirivimab plus imdevimab (REGEN-COV™) – Regeneron
  - Sotrovimab (formerly VIR-7831) – GSK and Vir
- **Each of these products targets the spike protein of SARS-CoV-2**



# Indications for Anti-SARS-CoV-2 Monoclonal Antibodies


---

■ Treatment

■ Prevention



- **Clinical trials demonstrated that early treatment with anti-SARS-CoV-2 monoclonal antibodies reduced the risk of COVID-19 hospitalization or death by 70-85%**



Key references and discussion at <https://www.covid19treatmentguidelines.nih.gov>



# People with Early SARS-CoV-2 Infection and These Conditions/Factors May Benefit from mAb Therapy

---

- Aged  $\geq 65$  years
- Obesity
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease) or hypertension
- Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
- Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation)

Sources: FDA; NIH COVID-19 Treatment Guidelines



# Indications for Anti-SARS-CoV-2 Monoclonal Antibodies

---

■ Treatment

■ Prevention





U.S. Department of Health & Human Services



U.S. Food and Drug Administration  
Protecting and Promoting Your Health

News Release

August 10, 2021

# **FDA Authorizes REGEN-COV Monoclonal Antibody Therapy for Post-exposure Prophylaxis (Prevention) for COVID-19**

- **EUA revised to allow use of REGEN-COV (casirivimab plus imdevimab) as PEP in adults and children >12 years at high risk for progression to severe COVID-19**





COVID-19 Treatment Guidelines

[www.covid19treatmentguidelines.nih.gov](http://www.covid19treatmentguidelines.nih.gov)

COMBATCOVID

Contact the Combat COVID  
Monoclonal Antibodies Call  
Center:

**1-877-332-6585**

<https://combatcovid.hhs.gov>





THE WHITE HOUSE  
WASHINGTON

WH.GOV